Same research group further assessed administration of HLA-mismatched iC9/CAR.19/IL15-transduced CB-NK cells in Phase I/II clinical trial to patients with r/r CD19- positive NHL and chronic lymphocytic leukemia (CLL) (164). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.